QIAGEN (NYSE:QGEN) Announces Earnings Results, Beats Estimates By $0.03 EPS
QIAGEN (NYSE:QGEN) announced its earnings results on Sunday. The company reported $0.66 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.03, MarketWatch Earnings reports. QIAGEN had a net margin of 11.18% and a return on equity of 17.51%. During the same period last year, the firm posted $0.34 earnings per share.
NYSE:QGEN traded up $0.32 during trading hours on Tuesday, hitting $47.94. 1,460,325 shares of the stock traded hands, compared to its average volume of 850,952. The firm has a 50 day moving average price of $50.11 and a 200 day moving average price of $50.93. The company has a current ratio of 1.46, a quick ratio of 1.22 and a debt-to-equity ratio of 0.52. QIAGEN has a fifty-two week low of $41.48 and a fifty-two week high of $59.00. The firm has a market cap of $10.93 billion, a price-to-earnings ratio of 58.73, a PEG ratio of 1.29 and a beta of 0.41.
Several equities analysts have recently weighed in on QGEN shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of QIAGEN in a research report on Tuesday. Nord/LB restated a “neutral” rating on shares of QIAGEN in a research report on Wednesday, January 6th. Berenberg Bank restated a “buy” rating on shares of QIAGEN in a research report on Friday, February 19th. Norddeutsche Landesbank restated a “hold” rating on shares of QIAGEN in a research report on Wednesday, January 6th. Finally, DZ Bank restated a “neutral” rating on shares of QIAGEN in a research report on Wednesday, April 7th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $59.92.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Featured Article: Risk Tolerance
Receive News & Ratings for QIAGEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QIAGEN and related companies with MarketBeat.com's FREE daily email newsletter.